

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

NOMO-1

RRID:CVCL_1609

Type: Cell Line

Proper Citation

RRID:CVCL_1609

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1609

Proper Citation: RRID:CVCL_1609

Description: Cell line NOMO-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Adult acute monocytic leukemia

Defining Citation: [PMID:1699657](#), [PMID:1701357](#), [PMID:9738977](#), [PMID:14671638](#), [PMID:20164919](#), [PMID:21552520](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27397505](#), [PMID:28109323](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NOMO-1

Synonyms: Nomo-1, NOMO1

Cross References: BTO:BTO_0005916, CLO:CLO_0009851, EFO:EFO_0022462, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:398, BioSample:SAMN01821652, BioSample:SAMN01821737, BioSample:SAMN03473105, BioSample:SAMN10988550, cancercellines:CVCL_1609, Cell_Model_Passport:SIDM00580, ChEMBL-Cells:ChEMBL3308243, ChEMBL-Targets:ChEMBL2366198, Cosmic:787464, Cosmic:908451, Cosmic:975286, Cosmic:1281342, Cosmic:1523827, Cosmic:1524839, Cosmic:2131550, Cosmic:2297030,

Cosmic:2306229, Cosmic-CLP:908451, DepMap:ACH-000168, DSMZ:ACC-542, DSMZCellDive:ACC-542, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10764-110E8, GDSC:908451, GEO:GSM236799, GEO:GSM236835, GEO:GSM482496, GEO:GSM887458, GEO:GSM888538, GEO:GSM1374774, GEO:GSM1446755, GEO:GSM1670283, IARC_TP53:21588, JCRB:IFO50474, LiGeA:CCLE_531, LINCS_LDP:LCL-1074, PharmacDB:NOMO1_1165_2019, PRIDE:PXD030304, Progenetix:CVCL_1609, PubChem_Cell_line:CVCL_1609, Wikidata:Q54930898

ID: CVCL_1609

Record Creation Time: 20220427T221346+0000

Record Last Update: 20260920T005313+0000

Ratings and Alerts

No rating or validation information has been found for NOMO-1.

No alerts have been found for NOMO-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Schäfer S, et al. (2026) ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia. Cell reports, 45(3), 117010.

Clayfield L, et al. (2026) Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. Cell reports, 45(2), 116875.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. bioRxiv : the preprint server for biology.

Peng J, et al. (2026) m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis. Cancer research communications, 6(4), 714.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

Lin H, et al. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. Cell reports. Medicine, 6(5), 102117.

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. *Cell reports*, 44(10), 116379.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. *Cell stem cell*, 32(3), 463.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. *Nature communications*, 16(1), 7793.

Han C, et al. (2025) An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance. *Blood cancer discovery*, 6(5), 464.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. *Cell reports. Medicine*, 5(7), 101645.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. *Cell reports*, 43(8), 114536.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. *Cell reports. Medicine*, 5(6), 101592.

Han L, et al. (2023) METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. *Cell stem cell*, 30(1), 52.

Popescu B, et al. (2023) Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. *Cell reports. Medicine*, 4(11), 101290.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Yabushita T, et al. (2023) Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. *Cell reports*, 42(9), 113098.

Ng M, et al. (2023) Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15. *iScience*, 26(10), 107844.

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V α 9V β 2-T cells for the treatment of CD1d-expressing hematological malignancies. *Cell reports. Medicine*, 4(3), 100961.